先声药业一类新药艾拉莫德获批 - 新药研发 - 快捷药讯

版块导航: 正在加载中...

客户端APP下载

论文辅导

申博辅导

登录注册

应《网络安全法》要求，自2017年10月1日起，未进行实名认证将不得使用互联网跟帖服务。为保障您的帐号能够正常使用，请尽快对帐号进行手机号验证，感谢您的理解与支持！

24小时热门版块排行榜

>论坛更新日志 (3116)
>虫友互识 (599)
>论文投稿 (196)
>休闲灌水 (163)
>基金申请 (133)
>导师招生 (110)
>文献求助 (105)
>公派出国 (69)
>硕博家园 (59)
>博后之家 (55)
>考博 (48)
>教师之家 (39)
>考研 (37)
>论文道贺祈福 (29)
>找工作 (28)
>绿色求助(高悬赏) (11)

返回列表

本帖产生 1 个 DRDEPI ，点击这里进行查看

当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

hardee

铁杆木虫 (知名作家)

此草有主~

DRDEPI: 12
应助: 152 (高中生)
贵宾: 0.03
金币: 10928.3
散金: 5544
红花: 49
沙发: 40
帖子: 6865
在线: 2905.6小时
虫号: 891544
注册: 2009-11-02
性别: GG
专业: 药物化学

★ ★
小木虫(金币+0.5):给个红包，谢谢回帖
zhychen2008(金币+1, DRDEPI+1): 多谢提供信息 2011-09-03 16:03:22

Meantime, Eisai and Toyama Chemical Co have submitted a marketing authorisation application for T-614 (iguratimod), an anti-rheumatic agent being jointly developed in Japan by the two companies.

T-614 is a novel disease modifying anti-rheumatic drug originally discovered by Toyama and an MAA was previously submitted in 2003. However, the application was temporarily withdrawn in 2009 in order to conduct an additional clinical study which subsequently confirmed with statistical significance the efficacy of the agent as an add-on therapy for use with the standard of care, methotrexate.

http://www.pharmatimes.com/Artic ... epsy_portfolio.aspx

只能说是先声的运气好了。。。

[ Last edited by hardee on 2011-9-1 at 15:17 ]